KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Expenditures (2016 - 2025)

Regeneron Pharmaceuticals has reported Capital Expenditures over the past 17 years, most recently at $248.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $248.7 million for Q4 2025, up 24.6% from a year ago — trailing twelve months through Dec 2025 was $898.4 million (up 18.85% YoY), and the annual figure for FY2025 was $898.4 million, up 18.85%.
  • Capital Expenditures for Q4 2025 was $248.7 million at Regeneron Pharmaceuticals, up from $201.4 million in the prior quarter.
  • Over the last five years, Capital Expenditures for REGN hit a ceiling of $391.8 million in Q3 2023 and a floor of -$102.8 million in Q2 2023.
  • Median Capital Expenditures over the past 5 years was $179.4 million (2023), compared with a mean of $175.7 million.
  • Biggest five-year swings in Capital Expenditures: plummeted 166.93% in 2023 and later surged 275.58% in 2024.
  • Regeneron Pharmaceuticals' Capital Expenditures stood at $154.9 million in 2021, then decreased by 1.74% to $152.2 million in 2022, then soared by 65.18% to $251.4 million in 2023, then decreased by 20.6% to $199.6 million in 2024, then grew by 24.6% to $248.7 million in 2025.
  • The last three reported values for Capital Expenditures were $248.7 million (Q4 2025), $201.4 million (Q3 2025), and $219.0 million (Q2 2025) per Business Quant data.